drugset / Trial / NCT00338390

Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC

NCT00338390

Phase 3 Completed 75 enrolled Hospital de Granollers
RandomizedParallel-groupOpen-labelTreatment

Summary

The study aims to ascertain whether the sole replacement of tenofovir with abacavir once a day improves the immunological response obtained with tenofovir + ddI or whether it is better to perform a double replacement of tenofovir and ddI with abacavir + lamivudine (joint formulation) in a single daily dose to achieve these objectives.

Timeline

Start
2005-04
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified 600 mg
Subject Didanosine Small molecule 250 mg
Subject Didanosine Small molecule 400 mg
Subject Lamivudine Other / unclassified 300 mg